Skip to main
SXTP

SXTP Stock Forecast & Price Target

SXTP Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

60 Degrees Pharmaceuticals Inc has demonstrated remarkable revenue growth, with net product revenues increasing 140% to $607.6k in FY24 and continuing this upward trend with a 223% year-over-year growth to $438 thousand in Q3 FY25. The increased sales of ARAKODA, which saw a 14% rise in deliveries, highlights the company's successful commercialization efforts for its key therapies amidst a growing market demand. Additionally, with a favorable safety profile for tafenoquine, there are promising opportunities for expanded clinical applications and commercialization potential, further supporting a positive outlook for the company's financial performance.

Bears say

60 Degrees Pharmaceuticals Inc is experiencing a challenging financial landscape, primarily driven by depressed forward multiples attributed to market volatility and a significant cash burn associated with various stages of development programs. The company reported a gross loss of approximately $9,000 in Q3 FY24, contrasting sharply with the previous year's gross profit of $36,000 due to a one-time inventory write-off, indicating potential operational inefficiencies. Additionally, low visibility on regulatory approvals and the risk of dilution from financing, paired with diminishing product demand and emerging resistance to key treatments, contribute to a cautious outlook for the company's financial stability and growth prospects.

SXTP has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 60 Degrees Pharmaceuticals Inc (SXTP) Forecast

Analysts have given SXTP a Strong Buy based on their latest research and market trends.

According to 2 analysts, SXTP has a Strong Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

60 Degrees Pharmaceuticals Inc (SXTP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.